Onyx invests in continuous flow following API demand

Onyx invests in continuous flow following API demand

UK API-maker and contract research organisation (CRO) Onyx Scientific is installing equipment for continuous flow manufacturing to offer customers an alternative to batch manufacturing.

Denise Bowser, Commercial Director, told in-Pharmatechnologist.com the company has spent £80,000 ($137,000) on equipment for its premises in Sunderland, northeast England citing customer demand for flexibility during process development.

Pharmaceutical clients ask for continuous flow during product R&D, she said, for “a wider range of conditions for certain experiments,” particularly surrounding hazardous reactions. “For us it’s a good thing to have the technology to give the clients full availability.

She added that continuous flow would make better use of the company’s space, give quicker output, and provide greater flexibility in compound manufacturing.

Continuous flow manufacturing – a technique that aims to lower costs and waste by integrating all stages of production – is “a very small area,” Bowser told us. The majority of Onyx’s API manufacturing will continue to be batch work, she said; “we’re just giving our clients further scope for developing using different techniques.

API investment

The equipment purchase comes as part of a wider investment initiative, with Onyx announcing it is increasing its GMP manufacturing capacity with extra vessels, following increased demand for GMP API manufacturing services for drug development.

The company reported a 45% rise in solid-state chemistry-related revenues last year, which it said was driven by early stage campaigns.

In May this year, it completed an API manufacturing deal for US firm Neuronascent, producing a 1kg consignment for use in the neurology company’s marketing authorisation submission to the US Food and Drug Administration.

As well as its Sunderland-based laboratories, Onyx has access to seven API sites in India for technology transfer, pilot-scale work, and manufacturing for Phase II through to commercial.

Related News

Onyx contracted for API R&D and manufacturing by UK cancer charity

Onyx contracted for API R&D and manufacturing by UK cancer charity

Continuous flow processing gets products to the scale-up phase faster, says Lonza

Lonza goes with the Flow Chemistry with latest API platform

The IPCA subsidiary is expanding its small scale API production facility

Onyx Scientific expands API facility on Phase I/II demand

Early adopter of continuous processing Janssen has installed a manufacturing line at its plant in Puerto Rico (photo c/o CIC Construction)

Janssen and Rutgers expand R&D as continuous manufacturing picks up steam

Image care of Onyx Scientific

Surging demand for APIs prompts expansion of second Onyx facility

SAFC expands continuous flow capacity in Wisconsin

SAFC expands continuous flow capacity in Wisconsin

Grant given to develop continuous flow crystallisation

Novasep riding on downstream tech and services in 2013

Continuous chromatography tech part of 'facility of the future,' says Novasep

Still work to be done downstream says GE Healthcare expert

Better single-use cross flow techs still needed says GE Healthcare